JP2015081244A - Acne treating pharmaceutical composition - Google Patents
Acne treating pharmaceutical composition Download PDFInfo
- Publication number
- JP2015081244A JP2015081244A JP2013220014A JP2013220014A JP2015081244A JP 2015081244 A JP2015081244 A JP 2015081244A JP 2013220014 A JP2013220014 A JP 2013220014A JP 2013220014 A JP2013220014 A JP 2013220014A JP 2015081244 A JP2015081244 A JP 2015081244A
- Authority
- JP
- Japan
- Prior art keywords
- acne
- pharmaceutical composition
- adapalene
- group
- tranexamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 41
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims abstract description 33
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 25
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 25
- 229960002916 adapalene Drugs 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 description 10
- 229940002658 differin Drugs 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- -1 dec-1-yl Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 241000186427 Cutibacterium acnes Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 229950005954 ibuprofen piconol Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BVYZDBLMCKSKAT-UHFFFAOYSA-N 2,2,3,3-tetrahexyldecanoic acid Chemical compound CCCCCCCC(CCCCCC)(CCCCCC)C(CCCCCC)(CCCCCC)C(O)=O BVYZDBLMCKSKAT-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- 150000005209 naphthoic acids Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 229950002760 sodium gualenate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- 229940030961 sorghum extract Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、ニキビ（尋常性ざ瘡）を治療するための新規な医薬組成物に関する。 The present invention relates to a novel pharmaceutical composition for treating acne (acne vulgaris).
ニキビ（尋常性ざ瘡）は、毛包に皮脂が詰まり、炎症をおこすことによって発症する皮膚の炎症性疾患である。主に思春期に発症し、顔面胸背部などに毛孔に一致して皮疹が認められる。ニキビの発症メカニズムは、面皰形成と炎症惹起の２つの段階があり、面皰形成には皮脂分泌の亢進、毛包漏斗部の角化異常、及び毛包内細菌［特にニキビ桿菌による。ニキビ桿菌はアクネ桿菌（プロピオニバクテリウム・アクネス；P．acnes）若しくはアクネ菌とも称される。］の増加が関与するといわれており、炎症惹起過程では、ニキビ桿菌由来の細胞外炎症誘発物質の関与が報告されている（例えば、非特許文献１参照）。これらのニキビの予防や治療には、洗顔や生活習慣の改善のほか、イオウ含有製剤、レチノイド様作用を有するナフトエ酸誘導体を有効成分とする外用薬のアダパレン（商品名：ディフェリン（登録商標）ゲル０．１％）（例えば、非特許文献２参照）、抗菌剤等が用いられている。 Acne (acne vulgaris) is an inflammatory disease of the skin that develops when the hair follicles are clogged with sebum and cause inflammation. It develops mainly in puberty, and skin eruptions are observed on the back of the face, chest and back, matching the pores. There are two stages of acne onset: comedone formation and inflammation. The formation of comedones involves increased sebum secretion, abnormal keratinization in the hair follicle funnel, and bacteria in the hair follicle [particularly due to acne bacilli. Acne gonococci are also called acne bacterium (Propionibacterium acnes; P. acnes) or acne bacterium. In the process of inducing inflammation, the involvement of an extracellular inflammation-inducing substance derived from acne is reported (for example, see Non-patent Document 1). For the prevention and treatment of acne, in addition to improving facial cleansing and lifestyle habits, adapalene (trade name: Differin (Registered Trademark) Gel), a topical drug containing sulfur-containing preparations and naphthoic acid derivatives having a retinoid-like action as active ingredients 0.1%) (for example, see Non-Patent Document 2), antibacterial agents and the like are used.
アダパレンは総皮疹（非炎症性皮疹及び炎症性皮疹）数を減少させる尋常性ざ瘡を治療する薬剤として知られている。その主な作用機序はレチノイド様作用による毛包漏斗部の表皮角化細胞の分化抑制で、ライノマウスでの用量依存的な面皰減少作用が知られている（例えば、非特許文献２参照）。しかしながら、アダパレンが炎症惹起過程に関与するニキビ桿菌の引き起こす炎症反応に対する抑制作用は知られていない。また、アダパレンは、ニキビに対して用量依存的な治療効果を有するが、皮膚乾燥、皮膚不快感、皮膚剥脱、紅斑等の副作用を高頻度で引き起こすことも、同時に知られている（例えば、非特許文献２参照）。 Adapalene is known as a drug for treating acne vulgaris that reduces the number of total rashes (non-inflammatory and inflammatory rashes). The main mechanism of action is suppression of differentiation of epidermal keratinocytes in the hair follicle funnel by retinoid-like action, and a dose-dependent comedone reducing action in rhino mice is known (for example, see Non-Patent Document 2). . However, adapalene is not known to have an inhibitory effect on the inflammatory response caused by acne koji molds involved in the inflammation-inducing process. Adapalene also has a dose-dependent therapeutic effect on acne, but is also known to cause frequent side effects such as skin dryness, skin discomfort, skin exfoliation, and erythema (for example, non- Patent Document 2).
トラネキサム酸は抗プラスミン剤として抗炎症作用等を示すことが知られている（例えば、非特許文献３参照）。 Tranexamic acid is known to exhibit an anti-inflammatory action and the like as an antiplasmin agent (see, for example, Non-Patent Document 3).
尋常性ざ瘡治療ガイドラインでは、炎症性皮疹に対しアダパレン外用のみではなく抗菌剤や非ステロイド性抗炎症薬（ＮＳＡＩＤｓ）との併用を推奨しており、アダパレンのみでは効果が不十分な場合があることも知られている（例えば、非特許文献４参照）。
アダパレンと併用される薬物として、タウリン、グルチルリチン酸二カリウム、酢酸トコフェロール、カンフル、メントール、イブプロフェンピコノール、乳酸メンチル、ジフェンヒドラミン、マレイン酸クロルフェニラミン等が知られているが（例えば、特許文献１〜５参照）、トラネキサム酸との併用、及び併用した場合の効果については知られていない。
Acne vulgaris treatment guidelines recommend not only topical use of adapalene but also antibacterial agents and non-steroidal anti-inflammatory drugs (NSAIDs) for inflammatory acne lesions, and adapalene alone may not be effective. It is also known (for example, refer nonpatent literature 4).
As drugs used in combination with adapalene, taurine, dipotassium glycyrrhizinate, tocopherol acetate, camphor, menthol, ibuprofen piconol, menthyl lactate, diphenhydramine, chlorpheniramine maleate and the like are known (for example, Patent Documents 1 to 1). 5)), combined use with tranexamic acid, and the effect of the combined use are not known.
本発明は、ニキビに対して、副作用が少なく有効性が高い医薬組成物を見出すことを課題とする。 An object of the present invention is to find a pharmaceutical composition that has little side effects and high efficacy against acne.
本発明者らは、鋭意研究の結果、ニキビ治療薬として知られているアダパレンに、抗プラスミン剤であるトラネキサム酸を併用することにより、ニキビの原因となるアクネ菌（プロピオニバクテリウム・アクネス）の感染による皮膚の腫脹に対し、極めて優れた効果を示すことを見出し、本発明を完成させた。 As a result of intensive research, the present inventors have used acne bacteria (propionibacterium acnes) causing acne by combining adapalene, which is known as an acne treatment, with tranexamic acid, an antiplasmin agent. As a result, the present invention was completed.
すなわち、本発明は、以下の（１）〜（４）に関する。
（１）アダパレン及びトラネキサム酸又はその塩を含有する、医薬組成物。
（２）トラネキサム酸又はその塩がトラネキサム酸である、上記（１）に記載の医薬組成物。
（３）ニキビ治療用である、上記（１）又は（２）に記載の医薬組成物。
（４）剤形が外用剤である、上記（１）〜（３）のいずれか１に記載の医薬組成物。
That is, the present invention relates to the following (1) to (4).
(1) A pharmaceutical composition comprising adapalene and tranexamic acid or a salt thereof.
(2) The pharmaceutical composition according to the above (1), wherein tranexamic acid or a salt thereof is tranexamic acid.
(3) The pharmaceutical composition according to the above (1) or (2), which is used for acne treatment.
(4) The pharmaceutical composition according to any one of (1) to (3) above, wherein the dosage form is an external preparation.
本発明により、優れたニキビの予防又は治療のための医薬組成物を得ることができる。 According to the present invention, an excellent pharmaceutical composition for preventing or treating acne can be obtained.
本発明に係るアダパレンの化学名は、6-[-3-(tricycle[3.3.1.13.7]dec-1-yl)-4-Methoxyphenyl]naphthalene-2-carboxylic acid（ＩＵＰＡＣ）であり、特公平８−３００１５号公報や特表２００８−５３４６４３号に記載されている方法で合成することができる。また、アダパレンを配合した製剤（ディフェリン（登録商標）０．１％ゲル）が市販されている。 The chemical name of adapalene according to the present invention is 6-[-3- (tricycle [3.3.1.13.7] dec-1-yl) -4-Methoxyphenyl] naphthalene-2-carboxylic acid (IUPAC). It can be synthesized by the methods described in JP-A-8-30015 and JP-T-2008-534643. In addition, a preparation containing adapalene (Differin (registered trademark) 0.1% gel) is commercially available.
本発明の医薬組成物におけるアダパレンの配合量は、製剤全体の重量に対し、通常０．００１〜５重量％であり、好ましくは、０．００２〜１重量％、さらに好ましくは、０．００５〜０．３重量％である。 The amount of adapalene in the pharmaceutical composition of the present invention is usually 0.001 to 5% by weight, preferably 0.002 to 1% by weight, more preferably 0.005 to 5% by weight based on the weight of the whole preparation. 0.3% by weight.
本発明におけるトラネキサム酸又はその塩は、公知の化合物であり、その入手方法としては、市販品を用いてもよく、また公知の方法に基づき製造することもできる。また、本発明におけるトラネキサム酸は、第１６改正日本薬局方に収載され、市販されており、容易に入手することができる。 Tranexamic acid or a salt thereof in the present invention is a known compound, and as a method for obtaining it, a commercially available product may be used, or it can be produced based on a known method. In addition, tranexamic acid in the present invention is listed in the 16th revised Japanese Pharmacopoeia, is commercially available, and can be easily obtained.
本発明におけるトラネキサム酸の塩としては、塩酸塩、硝酸塩、硫酸塩等の鉱酸塩、メタンスルホン酸塩等の有機酸塩、ナトリウム塩、カリウム塩、カルシウム塩、マグネシウム塩等のアルカリ金属塩、アルカリ土類金属塩等を挙げることができる。本発明においては、トラネキサム酸又はその塩としては、トラネキサム酸が好ましい。 Examples of the salt of tranexamic acid in the present invention include mineral salts such as hydrochloride, nitrate and sulfate, organic acid salts such as methanesulfonate, alkali metal salts such as sodium salt, potassium salt, calcium salt and magnesium salt, Examples thereof include alkaline earth metal salts. In the present invention, tranexamic acid or a salt thereof is preferably tranexamic acid.
本発明の医薬組成物におけるトラネキサム酸又はその塩の配合量は、製剤全体の重量に対し、通常０．０１〜１０重量％、好ましくは、０．０５〜５重量％であり、さらに好ましくは、０．１〜３重量％である。 The compounding amount of tranexamic acid or a salt thereof in the pharmaceutical composition of the present invention is usually 0.01 to 10% by weight, preferably 0.05 to 5% by weight, more preferably, based on the weight of the whole preparation. 0.1 to 3% by weight.
本発明の医薬組成物は、医薬品として、ニキビ（アクネ）の予防及び／ 又は治療を目的としている患者に投与するものである。 The pharmaceutical composition of the present invention is administered as a pharmaceutical to a patient whose purpose is prevention and / or treatment of acne (acne).
本発明の組成物には、さらに公知の抗ニキビ効果を示す成分や、抗ニキビ効果を増強する成分、及びニキビに伴う症状を緩和する成分を加えてもよい。これらの成分としては、例えば、グリンダマイシン、ナジフロキサシン、イオウ、イソプロピルメチルフェノール、ピオニン（感光素２０１号）、アラントイン、グリチルリチン酸ジカリウム、ピリドキシン塩酸塩、カラミン、グアイアズレンスルホン酸ナトリウム、グリチルレチン酸ステアリル、オウバクエキス等の殺菌、抗菌、抗炎症成分；イブプロフェンピコノール等の非ステロイド性抗炎症薬；ハマメリスエキス、エゾウコギエキス、クエン酸、シラカバエキス、緑茶エキス、ホップエキス等の収斂成分；グリコール酸、乳酸、サリチル酸、サリチル酸マクロゴール、サリチル酸エタノール、トリクロロ酢酸等のケミカルピーリング効果のある成分、アスコルビン酸、アスコルビン酸グルコシド、テトラヘキシルデカン酸アスコルビル等の抗酸化剤等を挙げることができる。 To the composition of the present invention, a component showing a known anti-acne effect, a component that enhances the anti-acne effect, and a component that alleviates symptoms associated with acne may be added. Examples of these components include lindamycin, nadifloxacin, sulfur, isopropylmethylphenol, pionine (photosensitive element 201), allantoin, dipotassium glycyrrhizinate, pyridoxine hydrochloride, calamine, sodium guaiazulene sulfonate, stearyl glycyrrhetinate, and oak extract. Bactericidal, antibacterial and anti-inflammatory ingredients such as ibuprofen piconol; non-steroidal anti-inflammatory drugs such as ibuprofen piconol; astringent ingredients such as hamamelis extract, sorghum extract, citric acid, birch extract, green tea extract and hop extract; glycolic acid, lactic acid , Macrogol salicylate, ethanol with salicylic acid, trichloroacetic acid and other chemical-peeling ingredients, ascorbic acid, ascorbyl glucoside, tetrahexyl decanoic acid ascorbic acid Antioxidants etc. and the like.
本発明の医薬組成物の剤形は、皮膚に適用される外用剤である。本発明の組成物の具体的な剤形としては、例えば、液剤、軟膏剤、クリーム等を挙げることができ、また、液剤を含浸させたマスクやテープ剤等を使用することができる。また、これら製剤を製造する際に、所望の添加物を配合することができる。本発明に配合できる添加剤としては、基剤、賦形剤、乳化剤、増粘剤、保湿剤、ｐＨ調節剤、香料等を挙げることができる。 The dosage form of the pharmaceutical composition of the present invention is an external preparation applied to the skin. Specific examples of the dosage form of the composition of the present invention include liquids, ointments, creams, and the like, and masks and tapes impregnated with liquids can be used. Moreover, a desired additive can be mix | blended when manufacturing these formulations. Examples of additives that can be blended in the present invention include bases, excipients, emulsifiers, thickeners, humectants, pH adjusters, and fragrances.
本発明の医薬組成物をニキビの患者に投与する際の用法用量としては、患者の病態等に応じて適宜調節することは可能だが、本発明の医薬組成物の剤形が外用剤の場合、患部に１日１回〜数回、患部に塗布すればよい。 The dosage for administration of the pharmaceutical composition of the present invention to acne patients can be appropriately adjusted according to the patient's pathology and the like, but when the dosage form of the pharmaceutical composition of the present invention is an external preparation, It may be applied to the affected area once to several times a day.
実施例を以下に記載するが、本発明はこれらに実施例のみに限定されるものではない。 Examples will be described below, but the present invention is not limited to these examples.
（試験例）マウスを用いたアクネ菌感染試験
１−１．試験方法
９週齢のＢＡＬＢ／ｃＡｎＮＣｒｌＣｒｌｊ系雄性マウス［日本チャールス・リバー（株）］を１週間馴化させた後、１０週齢のマウスにアクネ菌［プロピオニバクテリウム・アクネス，ＪＣＭ Ｎｏ．６４２５（独立法人理化学研究所）］２．５×１０７ｃｆｕを腹側正中部に皮内接種した。菌接種時の体重測定結果を用いて群分けを行い、菌接種４時間後の１回、翌日から１日１回投与物質を０．２ｍＬ（クリンダマイシン ゲル１％は０．２ｇ）塗布した。なお、トラネキサム酸とディフェリン（登録商標）ゲルの併用群についてはトラネキサム酸を塗布し、約１０分後、皮膚が乾いたのを確認した後ディフェリン（登録商標）ゲルを塗布した。菌接種後４日目に菌接種部位の腫脹部位の長径と短径を、電子ノギスを用いて測定した。下記式（１）により、面積を算出した。
(Test example) Acne bacteria infection test using mice 1-1. Test Method After acclimatization of 9-week-old BALB / cAnNCrlCrlj male mice [Nippon Charles River Co., Ltd.] for 1 week, acne bacteria [Propionibacterium acnes, JCM No. 6425 (RIKEN)] 2.5 × 10 7 cfu was inoculated intradermally on the ventral midline. Grouping was performed using the results of body weight measurement at the time of bacterial inoculation, and 0.2 mL (0.2 g of clindamycin gel 1%) was applied once 4 hours after bacterial inoculation and once a day from the next day. . In the combined use group of tranexamic acid and Differin (registered trademark) gel, tranexamic acid was applied, and after about 10 minutes, it was confirmed that the skin was dry, and then Differin (registered trademark) gel was applied. On the 4th day after the inoculation, the major axis and the minor axis of the swollen site of the inoculated site were measured using an electronic caliper. The area was calculated by the following formula (1).
１−２．被験物質
ディフェリン（登録商標）ゲル０．０１％は、ディフェリン（登録商標）ゲル０．１％［入手先：塩野義製薬(株)］に注射用水を加え調製し、塗布した。トラネキサム酸０．５％はトラネキサム酸［入手先：第一ファインケミカル(株)］をエタノール、１，３−ブタンジオール、注射用水（１:１:８）混液で溶解し調製し、塗布した。また、陽性対照薬として、アクネ菌を適応菌種に持つリンコマイシン系抗生物質のクリンダマイシン ゲル１％（外用抗生物質製剤）［入手先：クラシエ薬品(株)］を用い、薬剤をそのまま塗布した。
1-2. Test substance Differin (registered trademark) gel 0.01% was prepared by adding water for injection to Differin (registered trademark) 0.1% [source: Shionogi & Co., Ltd.] and applied. Tranexamic acid 0.5% was prepared by dissolving tranexamic acid [source: Daiichi Fine Chemical Co., Ltd.] in a mixed solution of ethanol, 1,3-butanediol, and water for injection (1: 1: 8), and then applied. Also, as a positive control drug, use 1% lincomycin antibiotic clindamycin gel (external antibiotic preparation) [acquired by Kracie Yakuhin Co., Ltd.], which has acne as an indication. did.
１−３．試験結果
各群１０匹の平均値を表２に示す。
薬剤の単独投与群である２群（アダパレン０．０１％投与群）及び３群（トラネキサム酸０．５％投与群）では、非投与群である１群と比べて腫脹面積の縮小傾向は見られたが、有意なものではなかった。一方、１群（非投与群）と比べて、４群（アダパレン０．０１％＋トラネキサム酸０．５％の併用投与群）及び５群（陽性対照群）は有意な腫脹面積の縮小が認められた。また、併用投与群である４群は、それぞれ単独投与群である２群（アダパレン０．０１％投与群）及び３群（トラネキサム酸０．５％投与群）と比べ、有意な腫脹面積の縮小が認められた。さらに、４群の併用投与群は５群（陽性対照群）よりも優れた効果が認められた。また、全ての投与群において、皮膚の痂皮や皮膚の発赤等の副作用は認められなかった。以上のことからアダパレンとトラネキサム酸を併用することにより、アクネ菌に対する抗腫脹作用はより強まり、しかも副作用等が認められず、優れた効果を奏することが分かった。
1-3. Test results Table 2 shows the average values of 10 animals in each group.
In the 2 groups (adapalene 0.01% administration group) and 3 groups (tranexamic acid 0.5% administration group), which are the single administration groups of the drug, there is a tendency for the swelling area to decrease compared to the non-administration group 1 group. Was not significant. On the other hand, compared with 1 group (non-administered group), 4 groups (Adapalene 0.01% + tranexamic acid 0.5% combined administration group) and 5 groups (positive control group) showed a significant reduction in the area of swelling. It was. In addition, group 4 which is the combination administration group has a significant reduction in the area of swelling compared with group 2 (adapalene 0.01% administration group) and group 3 (tranexamic acid 0.5% administration group) which are each single administration groups. Was recognized. Furthermore, the group 4 combined administration group was more effective than the group 5 (positive control group). In all administration groups, side effects such as skin scab and skin redness were not observed. From the above, it was found that by using adapalene and tranexamic acid in combination, the anti-swelling action against acne bacteria was further enhanced, and no side effects were observed, thereby producing an excellent effect.
（参考例）マウスを用いたアクネ菌感染試験２
２−１．試験方法
９週齢のＢＡＬＢ／ｃＡｎＮＣｒｌＣｒｌｊ系雄性マウス［日本チャールス・リバー（株）］を１週間馴化させた後、１０週齢のマウスにアクネ菌［プロピオニバクテリウム・アクネス，ＪＣＭ Ｎｏ．６４２５（独立法人理化学研究所）］２．５×１０７ｃｆｕを腹側正中部に皮内接種した。菌接種時の体重測定結果を用いて群分けを行い、菌接種４時間後の１回、翌日から１日１回投与物質を０．２ｍＬ塗布した。菌接種後４日目 に菌接種部位の腫脹部位の長径と短径を、電子ノギスを用いて測定した。下記式（２）に従って面積を算出した。
(Reference example) Acne bacteria infection test 2 using mice
2-1. Test Method After acclimatization of 9-week-old BALB / cAnNCrlCrlj male mice [Nippon Charles River Co., Ltd.] for 1 week, acne bacteria [Propionibacterium acnes, JCM No. 6425 (RIKEN)] 2.5 × 10 7 cfu was inoculated intradermally on the ventral midline. Grouping was performed using the results of body weight measurement at the time of bacterial inoculation, and 0.2 mL of a substance to be administered was applied once a day after 4 hours of bacterial inoculation and once a day from the next day. On the 4th day after the inoculation, the major axis and the minor axis of the swollen part of the inoculated part were measured using an electronic caliper. The area was calculated according to the following formula (2).
２−２．被験物質
ディフェリン（登録商標）ゲル０．１％はディフェリン（登録商標）ゲル０．１％［入手先：塩野義製薬(株)］をそのまま塗布した。陽性対照薬のクリンダマイシン ゲル１％［入手先：クラシエ薬品(株)］はそのまま塗布した。
2-2. Test substance Differin (registered trademark) gel 0.1% was directly coated with Differin (registered trademark) 0.1% [source: Shionogi & Co., Ltd.]. The positive control clindamycin gel 1% [source: Kracie Yakuhin Co., Ltd.] was applied as it was.
２−３．試験結果
各群１０匹の平均値を表４に示す。
６群（非投与群）と比べて、７群（アダパレン ０．１％投与群）及び陽性対照群の８群（クリンダマイシン ゲル１％投与群） は腫脹面積の有意な縮小が認められ、８群に比べ７群（アダパレン ０．１％投与群）の腫脹面積の縮小効果が、より大きい傾向が認められた。一方、７群（アダパレン ０．１％投与群）において、上記２群（アダパレン０．０１％投与群）では見られなかった軽度の皮膚の痂皮や皮膚の発赤の副作用が認められた。以上の結果より、アダパレン ０．１％の投与は、単独でもアクネ菌感染時の皮膚の腫脹面積を縮小する効果に優れるが、軽度の皮膚の痂皮や発赤といった副作用が認められた。
2-3. Test results Table 4 shows the average values of 10 animals in each group.
Compared with group 6 (non-administered group), group 7 (adapalene 0.1% administration group) and positive control group 8 group (clindamycin gel 1% administration group) showed a significant reduction in the swelling area, There was a tendency that the effect of reducing the area of swelling in group 7 (adapalene 0.1% administration group) was greater than that in group 8. On the other hand, in group 7 (adapalene 0.1% administration group), side effects of mild skin crusting and skin redness that were not seen in the above two groups (adapalene 0.01% administration group) were observed. From the above results, administration of adapalene 0.1% alone was excellent in the effect of reducing the swelling area of the skin when infected with acne, but side effects such as mild skin crusting and redness were observed.
（製剤例）
以下の表５の成分を用いて、常法（例えば、日本薬局方第１６改正 「11.6.ゲル剤」の製法を参照）によりゲル製剤を製造する。
(Formulation example)
Using the ingredients in Table 5 below, a gel preparation is produced by a conventional method (for example, refer to the method of preparation of “11.6. Gel Agent” in the 16th revision of the Japanese Pharmacopoeia).
本発明の、アダパレン及びトラネキサム酸を含有する医薬組成物は、アクネ菌によるニキビの患者に対して、副作用が少なく、有効性の優れた医薬組成物を提供できるので、有用である。 The pharmaceutical composition containing adapalene and tranexamic acid of the present invention is useful because it can provide an effective pharmaceutical composition with few side effects for acne patients caused by Acne bacteria.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013220014A JP2015081244A (en) | 2013-10-23 | 2013-10-23 | Acne treating pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013220014A JP2015081244A (en) | 2013-10-23 | 2013-10-23 | Acne treating pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2015081244A true JP2015081244A (en) | 2015-04-27 |
Family
ID=53012050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013220014A Pending JP2015081244A (en) | 2013-10-23 | 2013-10-23 | Acne treating pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2015081244A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017114769A (en) * | 2015-12-21 | 2017-06-29 | 第一三共ヘルスケア株式会社 | External pharmaceutical composition for treating acne |
| KR101822154B1 (en) * | 2016-06-20 | 2018-01-26 | (주)뷰티화장품 | Composition of functional cosmetics and over the counter drugs for treating and improving acne |
| JP2019218345A (en) * | 2018-06-16 | 2019-12-26 | ロート製薬株式会社 | External composition |
| JPWO2019240290A1 (en) * | 2018-06-16 | 2021-06-24 | ロート製薬株式会社 | Topical composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11193207A (en) * | 1997-12-26 | 1999-07-21 | Shiseido Co Ltd | Preparation for external use for skin |
| JP2005526063A (en) * | 2002-03-12 | 2005-09-02 | ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ | Use of adapalene to treat skin diseases |
-
2013
- 2013-10-23 JP JP2013220014A patent/JP2015081244A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11193207A (en) * | 1997-12-26 | 1999-07-21 | Shiseido Co Ltd | Preparation for external use for skin |
| JP2005526063A (en) * | 2002-03-12 | 2005-09-02 | ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ | Use of adapalene to treat skin diseases |
Non-Patent Citations (1)
| Title |
|---|
| 根本治ほか: "尋常性ざ瘡患者を対象とした低刺激性スキンケア化粧品NAVISION(R)(ナビジョン(R))の使用試験", 西日本皮膚科, vol. 72, no. 5, JPN6017028769, 2010, JP, pages 520 - 530, ISSN: 0003750478 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017114769A (en) * | 2015-12-21 | 2017-06-29 | 第一三共ヘルスケア株式会社 | External pharmaceutical composition for treating acne |
| KR101822154B1 (en) * | 2016-06-20 | 2018-01-26 | (주)뷰티화장품 | Composition of functional cosmetics and over the counter drugs for treating and improving acne |
| JP2019218345A (en) * | 2018-06-16 | 2019-12-26 | ロート製薬株式会社 | External composition |
| JPWO2019240290A1 (en) * | 2018-06-16 | 2021-06-24 | ロート製薬株式会社 | Topical composition |
| JP7299766B2 (en) | 2018-06-16 | 2023-06-28 | ロート製薬株式会社 | external composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8679552B2 (en) | Acne vulgaris treatment regimen | |
| KR20190037229A (en) | A synergistic antifungal composition and method thereof | |
| JP2015081244A (en) | Acne treating pharmaceutical composition | |
| TW201417822A (en) | Topical compositions for the treatment of acne | |
| JP2014501776A (en) | Melatonin and fungicides or antibacterial agents for the treatment of acne | |
| US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
| JP2011528377A (en) | Methods and materials for the treatment of acne | |
| JP2878353B2 (en) | External preparation for skin | |
| JP2017502053A (en) | Allantoin composition for treating inflammatory skin conditions | |
| JP6370094B2 (en) | Composition for suppressing yellowing of skin | |
| JP2017501232A (en) | Keloid reduction using local allantoin | |
| JPS63188628A (en) | Drug for skin external use | |
| JP2019043865A (en) | Skin external composition for treating or preventing acne-like disease | |
| JP2014114234A (en) | Skin external preparation | |
| CN110944649B (en) | Use of rhamnose and its derivatives as antifungal agents | |
| EP1670464A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| EP2588095B1 (en) | Composition for the treatment of acne vulgaris | |
| JP6679299B2 (en) | Topical pharmaceutical composition for treating acne | |
| JPH10265365A (en) | External preparation for skin for pimple | |
| KR101548254B1 (en) | Composition for treating skin disease comprising sulfur, alum and vinegar | |
| JP6180822B2 (en) | Pharmaceutical composition | |
| JP6025676B2 (en) | Weakly acidic aqueous external composition containing Photosensitive Element 201 | |
| JP5564648B2 (en) | Water-soluble zinc oxide composition | |
| JPH043363B2 (en) | ||
| JP4771453B2 (en) | Essence dosage form topical skin preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161004 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170726 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170802 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180305 |